April 12, 2019
(Washington, D.C.) —Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott released the following statement on bipartisan legislation introduced by Sens. Bill Cassidy (R-LA) and Dick Durbin (D-IL), the “Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act:”
“PCMA supports the REMEDY Act which proposes some common-sense changes to Food and Drug Administration law to promote more generic competition among prescription drugs, and help curb patent evergreening.
Pharmacy benefit managers’ (PBMs) ability to negotiate for lower drug costs hinges on competing products and generic or biosimilar alternatives. Unfortunately, brand drug manufacturer pricing and patent strategies can delay competition by preventing generics from entering the market.
We applaud Sens. Cassidy and Durbin and look forward to working with Congress and the Administration to reduce prescription drug costs.”